The semaglutide pill vs injection question is about delivery, not chemistry. Both contain semaglutide, a GLP-1 receptor agonist (a drug that mimics a gut hormone involved in appetite and blood sugar). The FDA-approved Wegovy tablet relies on an absorption enhancer and strict empty-stomach rules to be absorbed. The weekly injection bypasses digestion entirely. Each format beat placebo by a similar margin in its own trial, but no trial has compared them head to head.
Key takeaways
- FDA has approved Wegovy tablets, an oral semaglutide, and the current Wegovy label covers both the tablet and the injection.
- The tablet relies on an absorption enhancer called SNAC and an empty-stomach routine, while the injection skips the gut entirely.
- OASIS 4 (tablet) and STEP 1 (injection) each beat placebo by a similar margin in separate trials, so any comparison between them is approximate.
- Compounded oral, sublingual and dissolving semaglutide products have no published trial evidence comparable to the studies behind the approved products, and no FDA-approved reference product in that form.
- Format is a decision for an independent licensed clinician, and New Blue's semaglutide pathway is a compounded injection that is not FDA-approved.
Semaglutide pill vs injection: what FDA has approved
Yes, there is an FDA-approved semaglutide pill: Wegovy tablets. The current Wegovy prescribing information covers both the injection and the tablets, and the version cited here was revised in May 2026 (FDA Wegovy label, 2026).
The active ingredient is the same molecule in both formats. What changes is the packaging around it. The tablet contains semaglutide plus two inactive ingredients, salcaprozate sodium (SNAC) and magnesium stearate (FDA Wegovy label, 2026).
An oral semaglutide existed before this approval, but it was a different product approved for type 2 diabetes, not weight management. Diabetes data from that product does not answer the weight question, so this article leaves it out.
This article covers mechanism, evidence and regulation. It does not cover cost. For current pricing, see the treatment page linked in the access section below.
Why does the semaglutide pill need an empty stomach?
Semaglutide is a peptide, and digestion breaks peptides down before much of them can be absorbed. The tablet gets around this with an absorption enhancer, and absorption happens mainly in the stomach. Anything else in the stomach can interfere with that step.
A peptide is a short chain of amino acids, the same building blocks as protein. Stomach acid and digestive enzymes treat a peptide drug much like food. That is why most peptide medicines are injected.
SNAC is the absorption enhancer built into the approved tablet. The FDA label says the tablets are co-formulated with SNAC, which facilitates absorption of semaglutide after it is swallowed, and that absorption occurs predominantly in the stomach (FDA Wegovy label, 2026).
The label ties absorption to specific conditions: an empty stomach, the tablet kept whole, and a gap before food, other drinks or other oral medicines (FDA Wegovy label, 2026; DailyMed Wegovy label, 2026). The exact routine belongs to your clinician's guidance and pharmacy instructions.
The logic is simple. The enhancer and the drug are designed to act together, intact, in a mostly empty stomach. Food, coffee or a handful of other pills change those conditions. Breaking the tablet separates what was built to work as one unit.
The injection is subcutaneous, meaning it goes into the fatty tissue under the skin. It never passes through the stomach, so it has no meal-timing rules. For practical details on either format, follow your clinician's guidance and pharmacy instructions.
This mechanism matters for the compounding section below. If a product lacks the enhancer system that made the approved tablet work in trials, there is no evidence it is absorbed the same way.
OASIS 4 vs STEP 1: what each trial tested
OASIS 4 tested the daily tablet against placebo for 64 weeks. STEP 1 tested the weekly injection against placebo for 68 weeks. Neither trial included the other format, so neither one answers "pill or shot" directly.
| Feature | OASIS 4 (tablet) | STEP 1 (injection) |
|---|---|---|
| Design | Phase 3, randomized, placebo-controlled | Randomized, double-blind, placebo-controlled |
| Participants | 307 adults with overweight or obesity (205 semaglutide, 102 placebo) | 1,961 adults with overweight or obesity, without type 2 diabetes (1,306 semaglutide, 655 placebo) |
| Duration | 64 weeks | 68 weeks, with lifestyle intervention for all |
| Mean weight change | −13.6% vs −2.2% placebo | −14.9% vs −2.4% placebo |
| Gastrointestinal finding (different measures) | Any GI adverse event: 74.0% of the tablet group | Stopped because of GI events: 4.5% vs 0.8% placebo |
| Funding | Novo Nordisk | Novo Nordisk |
Sources for the table: OASIS 4 (NEJM, 2025) and STEP 1 (NEJM, 2021).
Both trials were funded by the manufacturer. That is normal for drug approval trials, but it is worth knowing. OASIS 4 was also much smaller. A published letter in NEJM noted that its cohort was predominantly White and female, which limits how well the results generalize (Liu et al. letter, NEJM 2025).
Is the semaglutide pill as effective as the shot?
No one can say precisely, because no head-to-head trial exists. In separate trials, the tablet beat placebo by an estimated 11.4 percentage points, while the injection group averaged −14.9% against −2.4% on placebo. The results look similar, but they are not proof the two formats are interchangeable.
The OASIS 4 gap comes from the published paper (NEJM, 2025). The STEP 1 figures are its reported group averages (NEJM, 2021). The trials enrolled different people, ran for different lengths of time and differed in size. Comparing across them is like comparing two races run on different courses.
The NEJM letter makes the same point. OASIS 4 had no active-comparator group, meaning no arm received another form of semaglutide. That limits any judgment of the tablet against the injection (Liu et al. letter, NEJM 2025).
Obesity trials often report two versions of the same result. A treatment-policy estimate counts everyone who was randomized, including people who stopped the drug or did not take it consistently. It answers the question "what happens to a group offered this treatment?"
An on-treatment estimate counts only what happened while people kept taking the drug as planned. It is usually higher, because it removes the dilution from people who stopped.
The −13.6% figure is the estimated mean change at week 64 reported in the NEJM paper (NEJM, 2025). These are group averages from specific trials, not predictions for any one person. Individual results vary, and no outcome is promised.
Both trials studied FDA-approved branded products. Their results do not transfer to compounded versions of semaglutide in any form.
Side effects and the safety screen both formats share
Both formats share the same main side effects and the same core safety screen. Gastrointestinal effects dominate, and both carry a boxed warning for thyroid C-cell tumors.
In OASIS 4, gastrointestinal adverse events were more common with the tablet than with placebo, affecting 74.0% of the tablet group (NEJM, 2025). In STEP 1, 4.5% of the injection group stopped because of gastrointestinal events, compared with 0.8% on placebo (NEJM, 2021). These are different measures, so they cannot be compared directly. The label also notes that semaglutide may slow how quickly the stomach empties (FDA Wegovy label, 2026).
A boxed warning is FDA's most prominent label warning. For Wegovy, it covers thyroid C-cell tumors. Semaglutide caused these tumors in rodents, and it is unknown whether it causes them in humans, including medullary thyroid carcinoma (MTC), a rare thyroid cancer. The label lists warning symptoms such as a lump in the neck, trouble swallowing, shortness of breath and persistent hoarseness (FDA Wegovy label, 2026). The label lists a personal or family history of MTC as a contraindication, meaning a reason not to use the drug (DailyMed Wegovy label, 2026).
People with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2), or a history of pancreatitis, should not use these medications. A clinician screens for this. MEN 2 is an inherited condition that raises the risk of certain endocrine tumors. For the pancreatitis evidence, see semaglutide pancreatitis risk in trials and labels.
This content is not for emergencies. Severe abdominal pain or a sudden change in vision needs urgent in-person care.
Why compounded oral and sublingual semaglutide raise concern
Compounded oral drops, sublingual (under-the-tongue) tablets and dissolving forms of semaglutide have no published trial evidence comparable to the studies behind the approved products. There is no FDA-approved product in those forms to measure them against.
A compounded medication is prepared by a state-licensed 503A compounding pharmacy or an FDA-registered 503B outsourcing facility rather than manufactured under an FDA approval. Compounded medications are not FDA-approved. Some compounders have created delivery forms with no approved counterpart. The approved Wegovy label covers an injection and a tablet, and nothing else (FDA Wegovy label, 2026).
There are three specific problems:
- No trial evidence. OASIS 4 and STEP 1 tested branded products. A sublingual drop has no comparable data on absorption, effect or safety.
- No absorption system. The approved tablet depends on SNAC and specific conditions for absorption. A product without that system cannot claim the same absorption, and the lining under the tongue is a different surface from the stomach.
- Quality and labeling. Without an approved reference product in the same form, there is no benchmark for absorption or strength.
For how regulators have acted on these products, see the patient guide to FDA warning letters on compounded GLP-1s.
How a clinician decides between formats
An independent licensed clinician decides based on your intake and clinical review. Not everyone qualifies. Eligibility depends on your health history, and that's how it should work.
Factors that usually come up:
- History and contraindications: MTC, MEN 2, pancreatitis and other conditions that rule out either format.
- Morning routine: whether you can reliably meet the tablet's empty-stomach and waiting conditions every day.
- Other oral medicines: anything you take in the morning that could conflict with the tablet's waiting period.
- Comfort with injections: needle aversion is a real factor, but so is the tablet's daily routine.
- Gastrointestinal history: prior tolerance of GLP-1 medicines or digestive conditions.
- Diabetes: the label says blood glucose is monitored before and during treatment in people with diabetes (FDA Wegovy label, 2026).
- Access: what is actually available to you.
Questions worth bringing to a clinician:
- Which format has trial evidence for my goal?
- What screening applies to me, and why?
- What should I do if side effects make it hard to continue?
The GLP-1 eligibility checklist covers what clinicians typically screen for.
How access works through New Blue
New Blue's semaglutide pathway is an injection only. New Blue does not offer an oral, sublingual or dissolving semaglutide, and it does not offer the Wegovy tablet.
New Blue is a technology and administrative services platform. Medical services are provided by independent licensed clinicians; medications are dispensed only if prescribed.
The pathway uses a compounded medication, and compounded medications are not FDA-approved. Compounded semaglutide has the same active ingredient as Ozempic and Wegovy (FDA-approved brand products), but it is a separately prepared product, not an approved version of either brand. It is prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities. The branded trial results above do not apply to it.
The process:
- You complete an asynchronous intake, meaning a structured online health questionnaire you fill out on your own schedule.
- An independent licensed clinician reviews it. Some treatments or states may require a live visit.
- If appropriate and if prescribed, a licensed partner pharmacy ships the medication directly to you.
Consultation timing varies by clinician availability. The semaglutide pathway can't ship to every state New Blue Health serves, so check your state on the state availability page. If you're not prescribed after the online review, all of what you paid comes back. If your state needs a video visit, everything except the cost of that visit comes back. See the refund policy.
New Blue is LegitScript certified, serves adults 21 and older, and is not for emergencies. For current pricing and details, see the semaglutide treatment page.
Frequently Asked Questions
Is the semaglutide pill as strong as the shot?
No trial has compared them directly, so there is no precise answer. In separate placebo-controlled trials, the tablet (OASIS 4) and the weekly injection (STEP 1) each beat placebo by a similar margin. The trials differed in size, population and length, so the comparison is only approximate.
Why can't the semaglutide pill be taken with coffee or breakfast?
Semaglutide is a peptide that digestion breaks down. The tablet relies on an absorption enhancer called SNAC, and absorption happens mainly in the stomach. Food, other drinks or other pills can interfere, which is why the label ties absorption to an empty stomach and a gap before food, other drinks or other oral medicines. The exact routine belongs to your clinician's guidance and pharmacy instructions.
Are semaglutide drops or under-the-tongue tablets FDA-approved?
No. The approved Wegovy label covers only an injection and a tablet. Compounded sublingual drops and dissolving tablets have no published trial evidence comparable to the studies behind the approved products, and compounded medications are not FDA-approved.
What is the FDA status of compounded injectable semaglutide?
Compounded injectable semaglutide is not FDA-approved, and no compounded medication is. Compounded semaglutide has the same active ingredient as Wegovy and Ozempic (FDA-approved brand products), but it is a separately prepared product, not an approved version of either. The branded trial results do not transfer to it.
Does the semaglutide pill have the same thyroid warning as the injection?
Yes. Both formats carry a boxed warning for thyroid C-cell tumors, which semaglutide caused in rodents. People with a personal or family history of MTC or MEN 2, or a history of pancreatitis, should not use these medications, and a clinician screens for this.
Does New Blue offer the Wegovy pill?
No. New Blue's semaglutide pathway is a compounded injection only and does not include the Wegovy tablet or any oral or sublingual form. New Blue is a technology and administrative services platform and does not prescribe; any prescription is a decision made by an independent licensed clinician after reviewing your intake.
Sources
- WEGOVY (semaglutide) injection and tablets – Highlights of Prescribing Information (revised 05/2026). U.S. Food and Drug Administration (Drugs@FDA), 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s031lbl218316s003lbl.pdf
- WEGOVY – semaglutide injection, solution; WEGOVY – semaglutide tablet (label). DailyMed, U.S. National Library of Medicine, 2026. https://www.dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b&type=pdf
- OASIS 4: once-daily oral semaglutide vs placebo in adults with overweight or obesity (randomized trial). The New England Journal of Medicine, 2025. https://pubmed.ncbi.nlm.nih.gov/40934115/
- Oral Semaglutide in Adults with Overweight or Obesity (letter, Liu, Sun, Wu). The New England Journal of Medicine, 2025. https://pubmed.ncbi.nlm.nih.gov/41370812/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 2021. https://pubmed.ncbi.nlm.nih.gov/33567185/
Medical disclaimer: This article is for educational purposes only and is not medical advice. Treatment decisions, including whether any medication is appropriate, are made by an independent licensed clinician based on your intake and clinical review. New Blue Health is a technology and administrative services platform, not a medical provider.
Related treatment guide
Related reading
Content review & editorial standards
This page is educational content from the New Blue Health Editorial Team. It is checked under the New Blue Health Content Review Policy and Editorial Policy and should not replace individualized medical advice from a licensed clinician. For how we evaluate evidence, see Evidence Methodology and Clinical Sources & References.